Watch PBYI. Know when insiders buy.
One email the day a filing lands. Free.
PBYI
PUMA BIOTECHNOLOGY, INC.
9.39
+0.14 +1.51%
USD · Sep 17, 08:20 a.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · insiders 29, shorts 44
Insiders, 90 days
−$612K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $484.7MP/E 18.1DIV YIELD —FCF YIELD 8.49%REV TTM $231.2M −2.9%NET INCOME $26.7M −44.9%NET CASH $25.2M52W 4.34 – 9.69SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $56.5M | +7.8% | 77.9% | $7.6M | $8.2M | +39.9% | 0.16 | $1.6M | $0 | $1.6M | Aug 6 |
| Q1 2026 · Mar 31 | $44.8M | −2.6% | 76.7% | −$3.8M | −$3.8M | −226.2% | -0.07 | $15.4M | $0 | $15.4M | May 7 |
| Q4 2025 · Dec 31derived | $75.5M | +27.7% | 69.3% | $17.1M | $13.4M | −30.4% | 0.26 | $14.4M | −$36K | $14.5M | Feb 26 |
| Q3 2025 · Sep 30 | $54.5M | −32.4% | 77.7% | $9.6M | $8.8M | −56.5% | 0.17 | $9.7M | $26K | $9.7M | Nov 6 |
| Q2 2025 · Jun 30 | $52.4M | +11.4% | 76.5% | $6.6M | $5.9M | — | 0.12 | $14.1M | $20K | $14.1M | Aug 6 |
| Q1 2025 · Mar 31 | $46M | +5.1% | 77.1% | $4M | $3M | — | 0.06 | $3.6M | $61K | $3.6M | May 7 |
| Q4 2024 · Dec 31derived | $59.1M | −18.2% | 76.4% | $13.4M | $19.3M | +57.4% | 0.40 | $15.6M | $16K | $15.6M | Feb 26 |
| Q3 2024 · Sep 30 | $80.5M | +43.5% | 63.9% | $22.1M | $20.3M | +250.5% | 0.41 | $11M | $20K | $11M | Nov 6 |
| Q2 2024 · Jun 30 | $47.1M | — | 77.4% | −$2.2M | −$4.5M | — | -0.09 | $1M | $20K | $1M | Aug 7 |
| Q1 2024 · Mar 31 | $43.8M | — | 75.5% | −$2.3M | −$4.8M | — | -0.10 | $11.2M | $0 | $11.2M | May 8 |
| Q4 2023 · Dec 31derived | $72.2M | — | 66.3% | $14.8M | $12.3M | — | 0.25 | $10.5M | $45K | $10.4M | Feb 26 |
| Q3 2023 · Sep 30 | $56.1M | — | 76.3% | $8.6M | $5.8M | — | 0.12 | $10.6M | $27K | $10.6M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $228.4M | 74.5% | $37.3M | $31.1M | 13.6% | 0.61 | $41.8M | $71K | $41.7M | — | — |
| FY2024 · to Dec 31 | $230.5M | 72.1% | $31M | $30.3M | 13.1% | 0.62 | $38.9M | $56K | $38.9M | — | — |
| FY2023 · to Dec 31 | $235.6M | 73.4% | $32.6M | $21.6M | 9.2% | 0.45 | $27M | $140K | $26.9M | — | — |
| FY2022 · to Dec 31 | $228M | 75.8% | $23.7M | $2K | 0.0% | 0.00 | −$15.8M | $0 | −$15.8M | — | — |
| FY2021 · to Dec 31 | $253.2M | 74.8% | $1.3M | −$29.1M | -11.5% | -0.72 | $20.6M | $0 | $20.6M | — | — |
| FY2020 · to Dec 31 | $225.1M | 82.5% | −$30.4M | −$60M | -26.7% | -1.52 | $773K | $46K | $727K | — | — |
Every number comes from PUMA BIOTECHNOLOGY, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.